Patents

The VASCADE® product is covered by one or more of the following US patents:

  • US 5,782,860
  • US 5,922,009
  • US 6,056,769
  • US 7,691,127
  • US 8,747,435
  • US 8,911,472
  • US 9,439,637

The CATALYST® II product is covered by one or more of the following US patents:

  • US 5,782,860
  • US 5,922,009
  • US 6,056,769
  • US 7,691,127
  • US 7,993,366
  • US 9,179,897
  • US 9,597,066

The CATALYST® III product is covered by one or more of the following US patents:

  • US 5,782,860
  • US 5,922,009
  • US 6,056,769
  • US 7,691,127
  • US 7,993,366
  • US 8,747,435

Cardiva Company Milestones

VASCADE MVP® receives FDA approval for 6-12F Inner Diameter (ID) multi-vessel venous vascular closure


Antegrade Study results published in Vascular Disease Management in 2018


VASCADE® receives FDA approval for use in femoral veins in 2018


VASCADE VCS approved by the FDA in 2013


VASCADE VCS approved for CE Mark in Europe in 2012


CATALYST III received 510(k) clearance in 2009


CATALYST II approved for CE Mark in Europe in 2008


CATALYST II received 510(k) clearance in 2007